Karyopharm Therapeutics Inc. (KPTI)

14.98
NASDAQ : Health Technology
Prev Close 14.77
Day Low/High 14.76 / 15.61
52 Wk Low/High 7.48 / 15.61
Avg Volume 198.20K
Exchange NASDAQ
Shares Outstanding 49.53M
Market Cap 653.84M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Noteworthy Friday Option Activity: KPTI, SAM, SIGM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Karyopharm Therapeutics Inc , where a total of 802 contracts have traded so far, representing approximately 80,200 underlying shares. That amounts to about 69.4% of KPTI's average daily trading volume over the past month of 115,550 shares.

Commit To Buy Karyopharm Therapeutics At $10, Earn 35.2% Annualized Using Options

Commit To Buy Karyopharm Therapeutics At $10, Earn 35.2% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc shares, but cautious about paying the going market price of $11.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $10 strike, which has a bid at the time of this writing of $1.65.

Karyopharm Therapeutics Stock Sees Short Interest Increase 16.4%

Karyopharm Therapeutics Stock Sees Short Interest Increase 16.4%

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 335,533 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,387,184, an increase of 16.35% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm To Present Phase 1b/2 STOMP Clinical Data At The American Society Of Hematology 2017 Annual Meeting

Karyopharm To Present Phase 1b/2 STOMP Clinical Data At The American Society Of Hematology 2017 Annual Meeting

- Fourteen Abstracts Selected, Including Three Oral Presentations -

Karyopharm To Report Third Quarter 2017 Financial Results On November 2, 2017

Karyopharm To Report Third Quarter 2017 Financial Results On November 2, 2017

Conference Call Scheduled for Thursday, November 2, 2017 at 8:30 a.m. ET

Karyopharm Therapeutics Stock Sees Short Interest Decline 17%

Karyopharm Therapeutics Stock Sees Short Interest Decline 17%

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 424,282 share decrease in total short interest for Karyopharm Therapeutics Inc , to 2,081,351, a decrease of 16.93% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.

Karyopharm To Report Second Quarter 2017 Financial Results On August 8, 2017

Karyopharm To Report Second Quarter 2017 Financial Results On August 8, 2017

Conference Call Scheduled for Tuesday, August 8, 2017 at 8:30 a.m. ET

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 19.7% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $9.34/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $7.50 strike, which has a bid at the time of this writing of 85 cents.

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

Earnings and Fed speakers are on tap in the next few days.

Karyopharm Therapeutics Stock Sees Short Interest Increase 13.3%

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 351,835 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,991,079, an increase of 13.33% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm Doses First Patient In Pivotal Phase 3 BOSTON Study Evaluating Selinexor In Patients With Relapsed/Refractory Multiple Myeloma

Enrollment Projected To Be Complete in 2018; Top-Line Data Expected in 2019

TheStreet Quant Rating: D (Sell)